Novartis and Eli Lilly sign separate $1.9bn novel drug deals

Novartis will work with a US biotech company on new cancer therapies, while Lilly has partnered with a Chinese biopharma firm to develop new medicines.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Regulation & Industry

Trump slaps 100% tariff on generic drugs in US manufacturing push

23 July 2026 Generic drug manufacturers face huge penalties if they fail to relocate production to the US within two years, with India among the countries expected to be hardest hit.

Regulation & Industry

UK Prime Minister axes science ministry in govt shakeup

22 July 2026 Plans to merge the UK’s standalone science ministry into an expanded business department, coupled with the departure of the Science Minister, mark a change in the country’s approach to science and innovation.

Regulation & Industry

Why is 2026 already a record year for M&A activity?

17 July 2026 Blockbuster acquisitions are back, impacting the pharma industry at record pace. As billions flow into breakthrough science, LSIPR’s series explores what’s driving the surge, how today’s deals are done, and where IP comes into the picture.

More features

FisherBroyles and Hong Kong affiliate draft in senior partners

‘Engagement and collaboration’: New IP Federation president builds on strong foundations

AbbVie, Allergan takes on Swiss aesthetics rival over syringe design

Trump slaps 100% tariff on generic drugs in US manufacturing push

Pharmascience v Janssen: Canada court updates methods of medical treatment protection

UK Prime Minister axes science ministry in govt shakeup

Masimo keeps $634m smartwatch award and moves to appeal

Arbutus takes Comirnaty LNP patent fight to Canada and UPC

Novartis and Eli Lilly sign separate $1.9bn novel drug deals

More on this story

Editor's picks

Editor's picks

More features